Drug intelligence / Profile preview

TRS005

Development stage: Phase 2
Lead developer: Zhejiang Teruisi Pharmaceutical
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TRS005 is a novel, proprietary antibody-drug conjugate (ADC) designed for the treatment of CD20-positive B-cell non-Hodgkin lymphoma. It consists of an anti-CD20 monoclonal antibody linked via a valine-citrulline linker to monomethyl auristatin E (MMAE), a potent microtubule-disrupting agent. The ADC binds to CD20 on tumor cells and is internalized through receptor-mediated endocytosis, delivering MMAE directly into the malignant B cells, leading to cell death. TRS005 has shown potential antitumor activity in relapsed or refractory B-cell non-Hodgkin lymphoma and is currently being evaluated in clinical trials for safety, pharmacokinetics, and efficacy[1][2][3][4].

Other names: anti-cd20 antibody-drug conjugate trs005anti-cd-20 antibody-drug conjugate trs005anti-cd 20 antibody-drug conjugate trs005

Targets

CD20 (B-lymphocyte antigen CD20)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on TRS005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRS005.

Explore the full profile